在创新药加速向机制升级、适应症精准拓展演进的趋势下，健康元药业在其呼吸系统疾病治疗主线之外，开始布局多元化创新领域。公司针对 ...

为探索 Na V 1.8 相关治疗，研究人员研究苏西曲吉宁（VX-548），发现其为 Na V 1.8 阻断剂，意义重大。

新京报讯3月24日，康弘药业（002773）发布公告，公司申报的KHN702片临床试验申请近日获得国家药监局签发的《药物临床试验批准通知书》。 KHN702片是康弘药业自主研发的高选择性NaV1.8抑制剂，是一种新型的非阿片类镇痛药物，无成瘾性，属于化药1类创新药。前期已完成的研究结果显示KHN702片安全性较好，且在多种疼痛模型中具有良好的治疗作用，预期临床应用前景较好。

KHN702片是公司自主研发的高选择性NaV1.8抑制剂，是一种新型的非阿片类镇痛药物，无成瘾性，属于化药1类创新药。前期已完成的研究结果显示KHN702片安全性较好，且在多种疼痛模型中具有良好的治疗作用，预期临床应用前景较好。

KHN702片是公司自主研发的高选择性NaV1.8抑制剂，是一种新型的非阿片类镇痛药物，无成瘾性，属于化药1类创新药。前期已完成的研究结果显示KHN702片安全性较好，且在多种疼痛模型中具有良好的治疗作用，预期临床应用前景较好。

Q4 2024 Earnings Call Transcript March 17, 2025 Sangamo Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ ...

Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid pain management drugs. | Latigo Biotherapeutics has whipped together a $150 ...

Latigo Biotherapeutics ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments ...

The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for its lead candidate.

Pacira BioSciences, Inc.'s stock is up 33%, backed by a new Exparel patent, growth strategies, and market trends. Click here to read why PCRX stock is a Buy.

Network pharmacology results suggest that voltage-gated sodium channel subtypes (Nav1.1, Nav1.2, and Nav1.6) may be the targets for RC prevention of DE. Furthermore, the Western blot analysis revealed ...

NaV1.7 hasn't yet gone to the clinic ... And that led to the conversion of that Phase 1/2 trial to a pivotal trial, which will have 50 people agreed to with the regulators; 50 people, we will ...